"We are pleased to enter into this facility with Avenue as it allows us to retire our existing indebtedness while providing the opportunity for additional non-dilutive financing in the future," said Dale Sander, Chief Financial Officer of Humacyte. "We are looking forward to an exciting 2026, including our plans for expanded use of Symvess® within the U.S. and international markets, interim results from our V012 Phase 3 trial in dialysis, and commencement of the first human study of our coronary tissue engineered vessel (CTEV) in coronary bypass graft surgery."
"We are excited to partner with Humacyte as it embarks on its next chapter of growth. Symvess is addressing significant patient needs and we are looking forward to supporting them in achieving success," said Chad Norman, Senior Portfolio Manager of Avenue Venture Opportunities Fund.
About Avenue Venture Opportunities
The Avenue Venture Debt Funds seek to provide creative financing solutions to high-growth, venture capital-backed technology and life science companies, focusing generally on companies within the underserved segment of the market created by the widening financing gap between commercial banks and larger debt funds. The Avenue Venture Debt funds are part of the larger group of funds of Avenue Capital Group. For additional information on Avenue Capital Group, which is a global investment firm with assets under management of more than $10 billion, visit www.avenuecapital.com.
About Humacyte
Humacyte, Inc. (NASDAQ:
